The role of GATA2 in lethal prostate cancer aggressiveness

Veronica Rodriguez-Bravo, Marc Carceles-Cordon, Yujin Hoshida, Carlos Cordon-Cardo, Matthew D. Galsky, Josep Domingo-Domenech

Research output: Contribution to journalReview article

22 Scopus citations

Abstract

Advanced prostate cancer is a classic example of the intractability and consequent lethality that characterizes metastatic carcinomas. Novel treatments have improved the survival of men with prostate cancer; however, advanced prostate cancer invariably becomes resistant to these therapies and ultimately progresses to a lethal metastatic stage. Consequently, detailed knowledge of the molecular mechanisms that control prostate cancer cell survival and progression towards this lethal stage of disease will benefit the development of new therapeutics. The transcription factor endothelial transcription factor GATA-2 (GATA2) has been reported to have a key role in driving prostate cancer aggressiveness. In addition to being a pioneer transcription factor that increases androgen receptor (AR) binding and activity, GATA2 regulates a core subset of clinically relevant genes in an AR-independent manner. Functionally, GATA2 overexpression in prostate cancer increases cellular motility and invasiveness, proliferation, tumorigenicity, and resistance to standard therapies. Thus, GATA2 has a multifaceted function in prostate cancer aggressiveness and is a highly attractive target in the development of novel treatments against lethal prostate cancer.

Original languageEnglish (US)
Pages (from-to)38-48
Number of pages11
JournalNature Reviews Urology
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 1 2017
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Urology

Cite this

Rodriguez-Bravo, V., Carceles-Cordon, M., Hoshida, Y., Cordon-Cardo, C., Galsky, M. D., & Domingo-Domenech, J. (2017). The role of GATA2 in lethal prostate cancer aggressiveness. Nature Reviews Urology, 14(1), 38-48. https://doi.org/10.1038/nrurol.2016.225